51¹ú²úÊÓƵ

Technology commercialisation company BTG will invest in Senexis, a biotechnology company that will develop treatments for ageing-related diseases such as Alzheimer's, Parkinson's and Huntington's.

Senexis, based at the 51¹ú²úÊÓƵ of Manchester Institute of Science and Technology, has raised ?1.4 million from BTG and Catalyst BioMedica Limited to finance its research.